Table 1.

Clinical characteristics of patients in the development and validation cohorts.

Characteristic at diagnosis		Oxford development [n = 111]		Cambridge validation [n = 96]		Uppsala validation [n = 298]
		ASC within 3 years of diagnosis n = 34 [31%]	No ASC within 3 years of diagnosis n = 77 [69%]	ASC within 3 years of diagnosis n = 25 [26%]	No ASC within 3 years of diagnosis n = 71 [74%]	ASC within 3 years of diagnosis n = 18 [6%]	No ASC within 3 years of diagnosis n = 280 [94%]
Median age [IQR]	years	37.4 [23.5, 42.8]	38.9 [25.8, 50.8]	48 [28, 63]	34 [25, 52]	30.5 [22.5, 54.8]	36 [25, 54.3]
Gender	M	15 [44%]	35 [45%]	15 [60%]	44 [62%]	9 [50%]	123 [44%]
	F	19 [56%]	42 [55%]	10 [40%]	27 [38%]	9 [50%]	157 [56%]
Extent	E1	1 [3%]	18 [23%]	0	18 [25%]	0	111 [40%]
	E2	17 [50%]	42 [56%]	5 [20%]	44 [62%]	3 [17%]	153 [55%]
	E3	16 [47%]	16 [21%]	20 [80%]	9 [9%]	15 [83%]	16 [5%]
Median CRP [IQR]	mg/l	14 [9.3, 43.8]	3.5 [2, 11]	23 [17, 36]	3 [2, 6]	19 [11, 53]	7 [3, 10]
Median haemoglobin [IQR]	g/dl	12 [11.3, 13.9]	13.4 [12.5, 14.6]	11.2 [10, 12]	13.5 [13, 14]	10.4 [10,11]	13.9 [13, 15]
Oral steroid therapy at diagnosis	[Yes]	27/77 [35%]	31/34 [91%]	Data not collected, since this did not form part of the predictive model
Endoscopy appearance	Mild/moderate	19 [56%]	74 [96%]
	Severe	15 [44%]	3 [4%]
Histopathology	Mild/moderate	20 [59%]	60 [78%]
	Severe	14 [42%]	17 [22%]
ASC outcomes	Complete response to steroids		14/34 [41%]
	Overall colectomy rate		10/34 [29%]

ASC, acute severe colitis; M, male; F, female; IQR, interquartile range.